Cargando…
Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1
Breast cancer cells have different requirements on metabolic pathways in order to sustain their growth. Triple negative breast cancer (TNBC), an aggressive breast cancer subtype relies mainly on glycolysis, while estrogen receptor positive (ER+) breast cancer cells possess higher mitochondrial oxida...
Autores principales: | Lucantoni, Federico, Dussmann, Heiko, Prehn, Jochen H. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141706/ https://www.ncbi.nlm.nih.gov/pubmed/30255019 http://dx.doi.org/10.3389/fcell.2018.00113 |
Ejemplares similares
-
BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose
por: Lucantoni, Federico, et al.
Publicado: (2018) -
Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release
por: Huber, Heinrich J, et al.
Publicado: (2011) -
Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells
por: Lucantoni, Federico, et al.
Publicado: (2018) -
Ketone body β-hydroxybutyrate (BHB) preserves mitochondrial bioenergetics
por: Llorente-Folch, I., et al.
Publicado: (2023) -
Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer
por: Dai, Wenting, et al.
Publicado: (2020)